NCT05107739

A Study of DeTIL-0255 in Adults With Advanced Malignancies

A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Nurix Therapeutics, Inc. · Industry
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.

Detailed description

This study includes a safety run in and a cohort expansion. The safety run in will include patients with any of the indications under study including: Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma Recurrent, metastatic, or persistent cervical carcinoma Advanced or recurrent endometrial cancer Cohort expansion will include patients with advanced malignancies who have received at least two prior systemic therapies in the same indications.

Conditions

• Platinum-resistant Ovarian Cancer
• Endometrial Cancer
• Cervical Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Drug Product De-TIL-0255	Autologous tumor-infiltrating lymphocytes

Timeline

• Start date: 2021-12-22
• Primary completion: 2023-05-09
• Completion: 2023-05-09
• First posted: 2021-11-04
• Last updated: 2024-05-03

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study